Oncopeptides Management

Management criteria checks 2/4

Oncopeptides' CEO is Sofia Heigis, appointed in Aug 2023, has a tenure of less than a year. total yearly compensation is SEK3.18M, comprised of 55.3% salary and 44.7% bonuses, including company stock and options. directly owns 0.02% of the company’s shares, worth SEK59.42K. The average tenure of the management team and the board of directors is 1.3 years and 6.5 years respectively.

Key information

Sofia Heigis

Chief executive officer

kr3.2m

Total compensation

CEO salary percentage	55.3%
CEO tenure	less than a year
CEO ownership	0.02%
Management average tenure	1.3yrs
Board average tenure	6.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Sofia Heigis's remuneration changed compared to Oncopeptides's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	kr3m	kr2m	-kr249m

Compensation vs Market: Sofia's total compensation ($USD291.27K) is about average for companies of similar size in the UK market ($USD346.19K).

Compensation vs Earnings: Insufficient data to compare Sofia's compensation with company performance.

CEO

Sofia Heigis (43 yo)

less than a year

Tenure

kr3,180,000

Compensation

Ms. Sofia Heigis, M.sc, was Chief Commercial Officer and Managing Director of Germany at Oncopeptides AB (publ) since 2022 until 07 August 2023 and also serves as its CEO since 07 August 2023. Ms. Heigis j...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Sofia Heigis	Chief Executive Officer	less than a year	kr3.18m	0.020% SEK 59.4k
Jakob Lindberg	Chief Scientific Officer	1.3yrs	kr4.84m	0.88% SEK 2.6m
Rolf Larsson	Founder	no data	no data	no data
Rolf Lewensohn	Founder	no data	no data	no data
Joachim Gullbo	Founder	no data	no data	no data
Kristina Luthman	Founder	no data	no data	no data
Hans Ehrsson	Founder	no data	no data	no data
Peter Nygren	Founder	no data	no data	no data
Henrik Bergentoft	Chief Financial Officer	less than a year	no data	no data
Eva Nordström	COO & Deputy MD	4.3yrs	no data	0.12% SEK 355.2k
Sara Svardgren	Head of Human Resources	5.9yrs	no data	0.000090% SEK 262.7

1.3yrs

Average Tenure

50yo

Average Age

Experienced Management: 0RN4's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Per Wold-Olsen	Independent Chairman of the Board	5.9yrs	kr1.63m	0.39% SEK 1.2m
Per Anders Samuelsson	Independent Director	12.3yrs	kr355.00k	no data
Cecilia Wennborg	Independent Director	7.2yrs	kr682.50k	0.012% SEK 34.9k
Lori Kunkel	Member of Clinical Advisory Board	no data	no data	no data
Jarl Jungnelius	Independent Director	13yrs	kr627.50k	0.058% SEK 170.6k
Brian Stuglik	Independent Director	5.9yrs	kr755.00k	no data
Christian Jacques	Member of Clinical Advisory Board	no data	no data	no data
Jennifer Jackson	Independent Director	5.3yrs	kr755.00k	no data
Axel Glasmacher	Member of Clinical Advisory Board	no data	no data	no data
Paul Richardson	Member of Clinical Advisory Board	no data	no data	no data

6.5yrs

Average Tenure

65yo

Average Age

Experienced Board: 0RN4's board of directors are considered experienced (6.5 years average tenure).

Oncopeptides Management

Management criteria checks 2/4

Key information

Recent management updates

Oncopeptides AB (publ), Annual General Meeting, May 22, 2024

Oncopeptides AB (publ) Announces the Nomination Committee

Oncopeptides AB (publ) Appoints Henrik Bergentoft as Chief Financial Officer

Oncopeptides AB (publ) Announces Sofia Heigis to Move from the CCO Role to CEO Role

Holger Lembrér Will Leave Oncopeptides as Chief Financial Officer

Oncopeptides AB (Publ) Announces Chief Financial Officer Changes

Recent updates

New minor risk - Shareholder dilution

Oncopeptides AB (Publ) Provides Sales Guidance for the First Quarter of 2024

Oncopeptides AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 300 million.

New major risk - Financial position

Oncopeptides AB (publ), Annual General Meeting, May 22, 2024

Oncopeptides Announces European Commission Decides to Formally Approve its Application to EMA for Extended Indication for Pepaxti into Earlier Lines

Oncopeptides AB (publ) to Report Q3, 2024 Results on Nov 07, 2024

Oncopeptides Selects to Present Additional Data from Ocean Study

New major risk - Financial position

Oncopeptides AB (publ) to Report Q2, 2024 Results on Aug 14, 2024

Oncopeptides AB (publ) Announces the Nomination Committee

Oncopeptides AB (publ) to Report Q1, 2024 Results on May 03, 2024

Oncopeptides AB (publ) to Report Fiscal Year 2023 Final Results on Apr 22, 2024

Oncopeptides AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024

Oncopeptides AB (Publ) Announces Positive Opinion on Type II Variation to Extend the Therapeutic Indication of Pepaxti Based on Ocean Trial Results

Oncopeptides AB (publ) Appoints Henrik Bergentoft as Chief Financial Officer

Oncopeptides AB (publ) Announces Sofia Heigis to Move from the CCO Role to CEO Role

Holger Lembrér Will Leave Oncopeptides as Chief Financial Officer

No longer forecast to breakeven

Oncopeptides AB (publ) to Report Q2, 2023 Results on Aug 10, 2023

Full year 2022 earnings released: kr4.11 loss per share (vs kr19.00 loss in FY 2021)

Forecast to breakeven in 2024

Oncopeptides AB (Publ) Announces Chief Financial Officer Changes

Oncopeptides AB (publ) Announces Jakob Lindberg Assumes Chief Scientific Officer

Oncopeptides AB (Publ) Announces Executive Changes

Oncopeptides AB (publ) Announces Nomination Committee Appointments

Oncopeptides AB (publ) to Report Fiscal Year 2022 Final Results on Apr 25, 2023

Oncopeptides Provides Update on Pepaxto US Marketing Authorization

Insufficient new directors

Oncopeptides AB (Publ) Announces Pepaxti Has Been Granted Marketing Authorization in the Uk

Oncopeptides AB (Publ) Announces the Market Potential for Pepaxti in Europe

Forecast to breakeven in 2024

Oncopeptides AB (publ), Annual General Meeting, May 25, 2023

Oncopeptides AB (publ) Announces Data from the Phase 3 Lighthouse Study

Oncopeptides AB (publ) Starts Commercialization of Pepaxti in Europe - Germany First Market

Oncopeptides AB (publ) Provides Update from Meeting with Advisory Committee ODAC

Oncopeptides AB (Publ) Receives SEK 5 Million Grant for Nk-Cell Engager Project in Multiple Myeloma

European Commission Approves Oncopeptides' Pepaxti for the Treatment of Patients with Relapsed Refractory Multiple Myeloma

Second quarter 2022 earnings released: kr0.79 loss per share (vs kr0.32 loss in 2Q 2021)

Forecast to breakeven in 2024

Now 31% undervalued

Oncopeptides AB (Publ) Issues A Positive Opinion Recommending Full Approval of Oncopeptides Peti in Eu for Patients with Tr Triple Class Refractory Multiple Myeloma

Oncopeptides AB (Publ) Announces That the European Medicines Agency´S Committee for Medicinal Products for Human Use

First quarter 2022 earnings released: kr1.31 loss per share (vs kr3.45 loss in 1Q 2021)

No longer forecast to breakeven

Insufficient new directors

Chief Executive Officer recently bought kr2.0m worth of stock

Oncopeptides AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023

No longer forecast to breakeven

Oncopeptides Rescinds Voluntary Withdrawal of Pepaxto in the US – No Intent to Market in the US at This Time

Independent Chairman of the Board recently bought kr1.4m worth of stock

Oncopeptides AB (Publ) Announces Data from Phase 3 Ocean Study Published in the Lancet Haematology

Insufficient new directors

Chief Executive Officer Martin Duvall has left the company

Chief Executive Officer Martin Duvall has left the company

Chief Executive Officer Martin Duvall has left the company

Chief Executive Officer Martin Duvall has left the company

Chief Executive Officer Martin Duvall has left the company

Chief Executive Officer Martin Duvall has left the company

Chief Executive Officer Martin Duvall has left the company

Chief Executive Officer Martin Duvall has left the company

Chief Executive Officer Martin Duvall has left the company

Chief Executive Officer Martin Duvall has left the company

Chief Executive Officer Martin Duvall has left the company

Chief Executive Officer Martin Duvall has left the company

Chief Executive Officer Martin Duvall has left the company

Chief Executive Officer Martin Duvall has left the company

Chief Executive Officer Martin Duvall has left the company

Chief Executive Officer Martin Duvall has left the company